Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

479 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313.
Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, Selim H, Rubin P, Ortiz H. Cox JD, et al. Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1191-5. doi: 10.1016/0360-3016(91)90227-u. Int J Radiat Oncol Biol Phys. 1991. PMID: 2045293 Clinical Trial.
Interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts. New evidence for accelerated proliferation from Radiation Therapy Oncology Group Protocol 8313.
Cox JD, Pajak TF, Marcial VA, Coia L, Mohiuddin M, Fu KK, Selim HM, Byhardt RW, Rubin P, Ortiz HG, et al. Cox JD, et al. Cancer. 1992 Jun 1;69(11):2744-8. doi: 10.1002/1097-0142(19920601)69:11<2744::aid-cncr2820691119>3.0.co;2-u. Cancer. 1992. PMID: 1571904 Clinical Trial.
A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. Cox JD, et al. J Clin Oncol. 1990 Sep;8(9):1543-55. doi: 10.1200/JCO.1990.8.9.1543. J Clin Oncol. 1990. PMID: 2167952 Clinical Trial.
Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials.
Cox JD, Pajak TF, Asbell S, Russell AH, Pederson J, Byhardt RW, Emami B, Roach M 3rd. Cox JD, et al. Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):493-8. doi: 10.1016/0360-3016(93)90371-2. Int J Radiat Oncol Biol Phys. 1993. PMID: 8226140 Clinical Trial.
The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)--analysis of a Radiation Therapy Oncology Group (RTOG) protocol.
Byhardt RW, Martin L, Pajak TF, Shin KH, Emami B, Cox JD. Byhardt RW, et al. Among authors: cox jd. Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):537-44. doi: 10.1016/0360-3016(93)90377-8. Int J Radiat Oncol Biol Phys. 1993. PMID: 8226146
479 results